BioAtla, Inc. (BCAB) Form 10-Q — May 15, 2026
BioAtla (BCAB) reported a Q1 2026 net loss of $6.3 million and disclosed substantial doubt about its ability to continue as a going concern, citing only $2.0 million in cash against a $552 million accumulated deficit. The company has initiated a formal process to explore strategic options, including the sale of assets or a potential merger, while simultaneously implementing a 70% workforce reduction to preserve capital. To address immediate liquidity needs, BioAtla entered into an amendment to its license agreement with Context Therapeutics, securing $6.5 million in payments ($4.5 million due within five business days and $2.0 million by August 2026).
Key figures
- Revenue
- 0
- Total Debt
- 45875000
- Total Assets
- 8566000
- Cash Position
- 1961000
- Ga expense q1 2025
- 5259000
- Ga expense q1 2026
- 4726000
- Rd expense q1 2025
- 12355000
- Rd expense q1 2026
- 4582000
- Accumulated deficit
- 551990000
- Reverse split ratio
- 50:1
- Sepa proceeds q1 2026
- 413000
- Sepa commitment amount
- 15000000
- Workforce reduction percent
- 70
- Shares outstanding post split
- 1656926
- Context license amendment payment 1
- 4500000
- Context license amendment payment 2
- 2000000
Price after filing
Close on the filing date to close N calendar days later (from $4.37). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.